share_log

The Total Return for Shandong Pharmaceutical GlassLtd (SHSE:600529) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

The Total Return for Shandong Pharmaceutical GlassLtd (SHSE:600529) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

在过去五年中,山东药用玻璃有限公司(SHSE: 600529)投资者的总回报增长速度超过了收益的增长
Simply Wall St ·  05/30 18:28

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) share price is up 40% in the last 5 years, clearly besting the market return of around 14% (ignoring dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 3.8% in the last year, including dividends.

我们在投资时一般寻求跑赢市场平均水平的股票。经过我们的经验来看,买入正确的股票可以显著提高财富。例如,山东药玻(SHSE:600529)股价在过去5年中上涨了40%,明显跑赢了市场回报约14%的状况(忽略分红)。然而,近期回报并不像那样令人印象深刻,包括分红在内,股票在过去一年中仅返回3.8%。

While the stock has fallen 3.2% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

尽管本周股票下跌了3.2%,但值得关注的是更长期的历史回报,并查看这些回报是否由基本面推动。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

虽然有效市场假说仍然被一些人教授,但被证明市场是过度反应的动态系统,投资者并不总是理性的。检查市场情绪如何随时间变化的一种方法是看一个公司的股价与其每股收益(EPS)之间的交互作用。

During five years of share price growth, Shandong Pharmaceutical GlassLtd achieved compound earnings per share (EPS) growth of 14% per year. This EPS growth is higher than the 7% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days.

在股票价格增长的五年中,山东药玻股份股份有限公司实现了每股收益增长的复合年增长率为14%。这种每股收益增长高于7%的股票价格年均增长率。因此,看起来市场对该股票并不那么热衷。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

该公司的每股收益(随时间的推移)如下图所示(单击可查看确切数字)。

earnings-per-share-growth
SHSE:600529 Earnings Per Share Growth May 30th 2024
SHSE:600529每股收益增长2024年5月30日

We know that Shandong Pharmaceutical GlassLtd has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

我们知道山东药玻股份股份有限公司最近改善了其底线,但它是否会增加营业收入呢?您可以查看这份显示分析师预测的营业收入的免费报告。

What About Dividends?

那么分红怎么样呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Shandong Pharmaceutical GlassLtd the TSR over the last 5 years was 46%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.

对于任何给定的股票,考虑总股东回报和股票价格回报都很重要。TSR包括任何分拆或折价筹资的价值,以及基于股息被再投资的假设而支付的任何股息。股息派发给股东,从而提高股东回报。我们注意到,对于山东药玻有限公司而言,过去5年的TSR为46%,优于上述股票价格回报。该公司支付的股息已促使其TSR得以提高。股东回报。

A Different Perspective

不同的观点

It's nice to see that Shandong Pharmaceutical GlassLtd shareholders have received a total shareholder return of 3.8% over the last year. And that does include the dividend. However, that falls short of the 8% TSR per annum it has made for shareholders, each year, over five years. Potential buyers might understandably feel they've missed the opportunity, but it's always possible business is still firing on all cylinders. Is Shandong Pharmaceutical GlassLtd cheap compared to other companies? These 3 valuation measures might help you decide.

山东药玻股份股份有限公司股东在过去一年中获得了3.8%的总股东回报。这确实包括分红。然而,与它在过去5年为股东每年创造的8%的TSR相比,这还不到。潜在的买家可能会理解地认为他们错过了机会,但业务仍然可能在全速运行。山东药玻股份股份有限公司是否与其他公司相比便宜?这3个估值措施可能有助于您作出决定。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您像我一样,就不会希望错过这份免费的内部人士正在购买的低估小市值股票列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发